Drop Testosterone (T) on Day 1

In the treatment of advanced prostate cancer (APC)

FIRMAGON® takes a more direct path to testosterone suppression than Leuprolide

Time to testosterone treatment goal

Day 1 = 52% reached their treatment goal

Day 3 = 96% reached their treatment goal

By day 28, both groups were similar

FIRMAGON IS AN ANTAGONIST

FIRMAGON is a gonadotropin-releasing hormone (GnRH) antagonist that stops testosterone suppression more directly at its main source, eliminating the possibility of an initial testosterone “surge” and any need for additional therapies to counteract surges.

FIRMAGON is a gonadotropin-releasing hormone (GnRH) antagonist available in the United States for the treatment of advanced prostate cancer (APC).

Time to testosterone treatment goal

By day 28, both groups were similar

LEUPROLIDE IS AN AGONIST

Leuprolide triggers a receptor called the luteinizing hormone–releasing hormone (LHRH) receptor, which results in an initial surge in testosterone. This initial surge subsequently reduces over a few weeks until T is suppressed. Additional medication may be required to prevent the effects of the testosterone surge.

FIRMAGON IS
AN ANTAGONIST

FIRMAGON is a gonadotropin-releasing hormone (GnRH) antagonist that immediately stops testosterone production at its source, eliminating the possibility of an initial testosterone “surge” and any need for additional therapies to counteract surges.

FIRMAGON is the only gonadotropin-releasing hormone (GnRH) antagonist available in the United States for the treatment of advanced prostate cancer (APC).

LEUPROLIDE IS
AN AGONIST

Leuprolide triggers a receptor called the luteinizing hormone–releasing hormone (LHRH) receptor, which results in an initial surge in testosterone. This initial surge subsequently reduces over a few weeks. Additional medication may be required to prevent the effects of the testosterone surge.

Get to T goal fast with FIRMAGON

FIRMAGON rapidly lowered T, nearly 90% on the first day

By day 28 of treatment, both FIRMAGON and Leuprolide achieved similar testosterone levels.

FIRMAGON gets you to T goal quickly

96% of FIRMAGON patients reached goal testosterone levels by day 3

Leuprolide initially increased testosterone levels—65% by the third day, compared to a 94% reduction with FIRMAGON. Some patients may require additional medication to prevent a symptomatic flare with Leuprolide.

TESTOSTERONE LEVELS IN THE FIRST 28 DAYS OF THERAPY

FIRMAGON (N=207)

Leuprolide (N=201)

Get to T goal fast with FIRMAGON

FIRMAGON dropped PSA levels*

PSA (prostate-specific antigen) reduction follows testosterone suppression. FIRMAGON dropped PSA levels by 95% by month 3.

FIRMAGON is proven to maintain PSA suppression through 12 months of treatment

Prostate-specific antigen (PSA) levels Prostate-specific antigen (PSA) levels

PSA level is a nonspecific measurement that may indicate cancer progression. These results should be evaluated with caution because of the broad range of patient types in the clinical study. No evidence has shown that the speed at which PSA declines is related to clinical benefit. Therefore, PSA level should not be seen on its own as evidence of the effectiveness of FIRMAGON.

Why T & PSA MATTER Before treatment

Have A Voice

Every month is an opportunity for you to connect with your treatment team

Make monthly visits matter by getting involved in your treatment plan.

 
Get the doctor discussion guide
I like the regularity of the monthly shot and the chance it gives me to build a relationship with my treatment team.
Actual patient quote
Hear From a Real FIRMAGON Patient
Get the doctor discussion guide